US payers do not expect the biosimilars market to be like the generics market.
US Payers do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars market to be like that in Europe, according to a report published by biotech giant Amgen.
While small molecule drugs are ideal for generics replication, biological drugs are not so simple. Biological drugs are usually large, complex molecular structures derived from or produced through a living organism, making them very difficult to replicate.
The Amgen survey of 40 different payers found that payer perceptions of biosimilars include:
• Payers anticipate biosimilars will be a strategy to reduce specialty drug prices and most (88%) believe the category represents a compelling business opportunity
• Most (80%) do not expect biosimilars to emulate the generics market; instead, payers expect to consider them as lower-cost branded options
• While there are analogues from the European commercial experience, at this time, few US payers are relying on Europe’s experience for US forecasting
The survey also showed that although US payers are eager for biosimilars to reduce specialty drug prices, Europe’s experience shows the level of savings may vary. European experience suggests that the most important conditions for market uptake of biosimilars are driven by factors such as physician perception, patient acceptance, local pricing and reimbursement regulations and procurement policies and terms. Amgen’s research also indicates that the US path may share few characteristics with the global experience to date.
The main difference between the US and Europe when it comes to biosimilars are interchangeability and substitution at the pharmacy level.
In Europe, the European Medicines Agency does not make any evaluation of interchangeability and individual Member States decide whether a biosimilar may be substituted at the pharmacy or not. In the US, the Food and Drug Administration (FDA) has the authority to make a decision on interchangeability. In addition, the Biologics Price Competition and Innovation (BPCI) Act gives FDA the authority to designate a biosimilar as interchangeable with its reference product. This means that the biosimilar may be substituted for the originator product by the pharmacist without reference to the prescribing physician.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.